<DOC>
	<DOCNO>NCT01454102</DOCNO>
	<brief_summary>There formal research hypothesis statistically test protocol . - The study evaluate safety tolerability Nivolumab ( BMS-936558 ) combine three platinum-based doublet chemotherapy regimen ( Cisplatin/Gemcitabine ; Cisplatin/Pemetrexed ; Carboplatin/Paclitaxel ) subject NSCLC . - The study evaluate safety tolerability Nivolumab maintenance therapy combination Bevacizumab/Avastin give least 4 cycle platinum doublet chemotherapy . - The study evaluate safety tolerability Nivolumab combination Erlotinib among epidermal growth factor receptor ( EGFR ) mutation positive non-squamous NSCLC subject monotherapy subject NSCLC . - The study evaluate safety tolerability Nivolumab combination Ipilimumab subject squamous non-squamous NSCLC . - The study evaluate safety tolerability Nivolumab switch maintenance therapy subject squamous non-squamous NSCLC . - The study evaluate safety tolerability Nivolumab monotherapy among subject untreated , asymptomatic brain metastasis evidence cerebral edema .</brief_summary>
	<brief_title>Study Nivolumab ( BMS-936558 ) Combination With Gemcitabine/Cisplatin , Pemetrexed/Cisplatin , Carboplatin/Paclitaxel , Bevacizumab Maintenance , Erlotinib , Ipilimumab Monotherapy Subjects With Stage IIIB/IV Non-small Cell Lung Cancer ( NSCLC ) ( CheckMate 012 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Newly diagnose confirm Stage IIIB/IV NSCLC Previously treat NSCLC asymptomatic brain metastasis ( eligible Arm M ) See additional detail Men woman age ≥18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Subject must chemotherapy naive ( except Arm D , K , L M ) . Prior use epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI ) acceptable . For Arms D , K , L , subject must nonprogressors within 42 day completion firstline treatment ≥4 cycle Platinum Doublet chemotherapy without Bevacizumab . See Arm M Either formalin fixed tissue block minimum 10 slide tumor sample ( archived fresh ) must available biomarker evaluation ( local pathologist must review adequacy sample ) Life expectancy least 3 month Prior radiotherapy must complete least 2 week prior study entry For Arm M : No 4 brain metastasis Each brain metastases ≤3 cm size No evidence cerebral edema Subjects must free neurologic symptom relate metastatic brain lesion must require received systemic corticosteroid ≥10 day prior initiation study treatment At least 1 measurable target brain lesion &gt; 0.5 cm large 3 cm diameter and/or 2 measurable brain target lesion &gt; 0.3 cm No prior radiation therapy , surgery , local therapy target brain lesion Must receive least one prior systemic anticancer therapy NSCLC Subjects symptomatic brain metastasis , spinal cord compression , intractable back pain due compressive destructive mass Subjects require emergent use systemic steroid , emergent surgery and/or radiotherapy Any active history know autoimmune disease Subjects previous malignancy ( except nonmelanoma skin cancer , situ bladder cancer , gastric , colon cancer cervical cancers/dysplasia , breast carcinoma situ ) exclude unless complete remission achieve least 2 year prior study entry additional therapy require anticipate required study period History Grade ≥2 neuropathy Subjects interstitial lung disease symptomatic may interfere detection management suspect drugrelated pulmonary toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>